Drug Profile
Research programme: Parkinson's disease therapeutics - Araclon Biotech
Alternative Names: AB 03Latest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator Araclon Biotech
- Developer Araclon Biotech; CSIC
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 24 Jul 2023 Discontinued - Preclinical for Parkinson's disease in Spain (unspecified route)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Parkinson's-disease in Spain
- 07 Oct 2016 Preclinical development of the research programme is still ongoing in Spain